Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Accounts Payables (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Accounts Payables for 11 consecutive years, with $140000.0 as the latest value for Q4 2025.

  • For Q4 2025, Accounts Payables changed N/A year-over-year to $140000.0; the TTM value through Dec 2025 reached $140000.0, changed N/A, while the annual FY2025 figure was $140000.0, N/A changed from the prior year.
  • Accounts Payables hit $140000.0 in Q4 2025 for Crescent Biopharma, down from $2.6 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $5.0 million in Q2 2025 and bottomed at $104671.0 in Q1 2025.
  • Average Accounts Payables over 5 years is $1.3 million, with a median of $950763.0 recorded in 2024.
  • On a YoY basis, Accounts Payables climbed as much as 427.89% in 2025 and fell as far as 86.15% in 2025.
  • Crescent Biopharma's Accounts Payables stood at $2.1 million in 2021, then plummeted by 53.97% to $970191.0 in 2022, then fell by 10.52% to $868115.0 in 2023, then tumbled by 32.98% to $581794.0 in 2024, then crashed by 75.94% to $140000.0 in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $140000.0, $2.6 million, and $5.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.